Analyst Suraj Kalia initiated a $buy rating on $Humacyte (HU...

Analysts believe Humacyte has pioneered a type of blood vessel with human cells for transplantation, and see commercial opportunities for the company in dialysis and vascular trauma markets. It has also offered a "call option" on type 1 diabetes, which could alter existing treatment paradigms.